SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses
Issued Date
2022-02-03
Resource Type
ISSN
00928674
eISSN
10974172
Scopus ID
2-s2.0-85123365266
Pubmed ID
35081335
Journal Title
Cell
Volume
185
Issue
3
Start Page
467
End Page
484.e15
Rights Holder(s)
SCOPUS
Bibliographic Citation
Cell Vol.185 No.3 (2022) , 467-484.e15
Suggested Citation
Dejnirattisai W., Huo J., Zhou D., Zahradník J., Supasa P., Liu C., Duyvesteyn H.M.E., Ginn H.M., Mentzer A.J., Tuekprakhon A., Nutalai R., Wang B., Dijokaite A., Khan S., Avinoam O., Bahar M., Skelly D., Adele S., Johnson S.A., Amini A., Ritter T.G., Mason C., Dold C., Pan D., Assadi S., Bellass A., Omo-Dare N., Koeckerling D., Flaxman A., Jenkin D., Aley P.K., Voysey M., Costa Clemens S.A., Naveca F.G., Nascimento V., Nascimento F., Fernandes da Costa C., Resende P.C., Pauvolid-Correa A., Siqueira M.M., Baillie V., Serafin N., Kwatra G., Da Silva K., Madhi S.A., Nunes M.C., Malik T., Openshaw P.J.M., Baillie J.K., Semple M.G., Townsend A.R., Huang K.Y.A., Tan T.K., Carroll M.W., Klenerman P., Barnes E., Dunachie S.J., Constantinides B., Webster H., Crook D., Pollard A.J., Lambe T., Conlon C., Deeks A.S., Frater J., Frending L., Gardiner S., Jämsén A., Jeffery K., Malone T., Phillips E., Rothwell L., Stafford L., Baillie J.K., Openshaw P.J., Carson G., Alex B., Andrikopoulos P., Bach B., Barclay W.S., Bogaert D., Chand M., Chechi K., Cooke G.S., da Silva Filipe A., de Silva T., Docherty A.B., dos Santos Correia G., Dumas M.E., Dunning J., Fletcher T., Green C.A., Greenhalf W., Griffin J.L., Gupta R.K., Harrison E.M., Hiscox J.A., Wai Ho A.Y., Horby P.W., Ijaz S. SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses. Cell Vol.185 No.3 (2022) , 467-484.e15. 484.e15. doi:10.1016/j.cell.2021.12.046 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/87497
Title
SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses
Author(s)
Dejnirattisai W.
Huo J.
Zhou D.
Zahradník J.
Supasa P.
Liu C.
Duyvesteyn H.M.E.
Ginn H.M.
Mentzer A.J.
Tuekprakhon A.
Nutalai R.
Wang B.
Dijokaite A.
Khan S.
Avinoam O.
Bahar M.
Skelly D.
Adele S.
Johnson S.A.
Amini A.
Ritter T.G.
Mason C.
Dold C.
Pan D.
Assadi S.
Bellass A.
Omo-Dare N.
Koeckerling D.
Flaxman A.
Jenkin D.
Aley P.K.
Voysey M.
Costa Clemens S.A.
Naveca F.G.
Nascimento V.
Nascimento F.
Fernandes da Costa C.
Resende P.C.
Pauvolid-Correa A.
Siqueira M.M.
Baillie V.
Serafin N.
Kwatra G.
Da Silva K.
Madhi S.A.
Nunes M.C.
Malik T.
Openshaw P.J.M.
Baillie J.K.
Semple M.G.
Townsend A.R.
Huang K.Y.A.
Tan T.K.
Carroll M.W.
Klenerman P.
Barnes E.
Dunachie S.J.
Constantinides B.
Webster H.
Crook D.
Pollard A.J.
Lambe T.
Conlon C.
Deeks A.S.
Frater J.
Frending L.
Gardiner S.
Jämsén A.
Jeffery K.
Malone T.
Phillips E.
Rothwell L.
Stafford L.
Baillie J.K.
Openshaw P.J.
Carson G.
Alex B.
Andrikopoulos P.
Bach B.
Barclay W.S.
Bogaert D.
Chand M.
Chechi K.
Cooke G.S.
da Silva Filipe A.
de Silva T.
Docherty A.B.
dos Santos Correia G.
Dumas M.E.
Dunning J.
Fletcher T.
Green C.A.
Greenhalf W.
Griffin J.L.
Gupta R.K.
Harrison E.M.
Hiscox J.A.
Wai Ho A.Y.
Horby P.W.
Ijaz S.
Huo J.
Zhou D.
Zahradník J.
Supasa P.
Liu C.
Duyvesteyn H.M.E.
Ginn H.M.
Mentzer A.J.
Tuekprakhon A.
Nutalai R.
Wang B.
Dijokaite A.
Khan S.
Avinoam O.
Bahar M.
Skelly D.
Adele S.
Johnson S.A.
Amini A.
Ritter T.G.
Mason C.
Dold C.
Pan D.
Assadi S.
Bellass A.
Omo-Dare N.
Koeckerling D.
Flaxman A.
Jenkin D.
Aley P.K.
Voysey M.
Costa Clemens S.A.
Naveca F.G.
Nascimento V.
Nascimento F.
Fernandes da Costa C.
Resende P.C.
Pauvolid-Correa A.
Siqueira M.M.
Baillie V.
Serafin N.
Kwatra G.
Da Silva K.
Madhi S.A.
Nunes M.C.
Malik T.
Openshaw P.J.M.
Baillie J.K.
Semple M.G.
Townsend A.R.
Huang K.Y.A.
Tan T.K.
Carroll M.W.
Klenerman P.
Barnes E.
Dunachie S.J.
Constantinides B.
Webster H.
Crook D.
Pollard A.J.
Lambe T.
Conlon C.
Deeks A.S.
Frater J.
Frending L.
Gardiner S.
Jämsén A.
Jeffery K.
Malone T.
Phillips E.
Rothwell L.
Stafford L.
Baillie J.K.
Openshaw P.J.
Carson G.
Alex B.
Andrikopoulos P.
Bach B.
Barclay W.S.
Bogaert D.
Chand M.
Chechi K.
Cooke G.S.
da Silva Filipe A.
de Silva T.
Docherty A.B.
dos Santos Correia G.
Dumas M.E.
Dunning J.
Fletcher T.
Green C.A.
Greenhalf W.
Griffin J.L.
Gupta R.K.
Harrison E.M.
Hiscox J.A.
Wai Ho A.Y.
Horby P.W.
Ijaz S.
Author's Affiliation
Mahidol Oxford Tropical Medicine Research Unit
NIHR Oxford Biomedical Research Centre
Oxford University Hospitals NHS Foundation Trust
Texas A&M College of Veterinary Medicine & Biomedical Sciences
Public Health England
Diamond Light Source
University of the Witwatersrand Faculty of Health Sciences
Chang Gung University College of Medicine
University of Leicester
University Hospitals of Leicester NHS Trust
University of Oxford
University of Edinburgh, Roslin Institute
Fundacao Oswaldo Cruz
University of Liverpool
Fiocruz Amazônia
Weizmann Institute of Science Israel
School of Pathology
National Heart and Lung Institute
Nuffield Department of Medicine
Università degli Studi di Siena
University of Oxford Medical Sciences Division
Fundação de Vigilância em Saúde do Amazonas
NIHR Oxford Biomedical Research Centre
Oxford University Hospitals NHS Foundation Trust
Texas A&M College of Veterinary Medicine & Biomedical Sciences
Public Health England
Diamond Light Source
University of the Witwatersrand Faculty of Health Sciences
Chang Gung University College of Medicine
University of Leicester
University Hospitals of Leicester NHS Trust
University of Oxford
University of Edinburgh, Roslin Institute
Fundacao Oswaldo Cruz
University of Liverpool
Fiocruz Amazônia
Weizmann Institute of Science Israel
School of Pathology
National Heart and Lung Institute
Nuffield Department of Medicine
Università degli Studi di Siena
University of Oxford Medical Sciences Division
Fundação de Vigilância em Saúde do Amazonas
Other Contributor(s)
Abstract
On 24th November 2021, the sequence of a new SARS-CoV-2 viral isolate Omicron-B.1.1.529 was announced, containing far more mutations in Spike (S) than previously reported variants. Neutralization titers of Omicron by sera from vaccinees and convalescent subjects infected with early pandemic Alpha, Beta, Gamma, or Delta are substantially reduced, or the sera failed to neutralize. Titers against Omicron are boosted by third vaccine doses and are high in both vaccinated individuals and those infected by Delta. Mutations in Omicron knock out or substantially reduce neutralization by most of the large panel of potent monoclonal antibodies and antibodies under commercial development. Omicron S has structural changes from earlier viruses and uses mutations that confer tight binding to ACE2 to unleash evolution driven by immune escape. This leads to a large number of mutations in the ACE2 binding site and rebalances receptor affinity to that of earlier pandemic viruses.